A Phase II Trial of Regadenoson in Sickle Cell Anemia

 

danafarber

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug called Regadenoson (or Lexiscan) to learn whether the drug works in treating a specific disease, in this case Sickle Cell Disease (SCD). In this research study, the investigators are specifically looking to see if Regadenoson is an effective treatment for pain crises and acute chest syndrome in SCD.

 

More Information: clinicaltrials.gov, ITHANET Clinical Trials